公开(公告)号：WO2008071870A3

公开(公告)日：2008-08-14

申请号：PCT/FR2007001926

申请日：2007-11-23

Applicant: SERVIER LAB ,  MOCAER ELISABETH ,  FABIANO AGNES

Inventor： MOCAER ELISABETH ,  FABIANO AGNES

IPC: A61K31/165 ,  A61P25/00

CPC classification number: A61K31/165

Abstract: The invention relates to the use of agomelatine or N-[2-(7-methoxy-1-naphtyl)ethyl]acetamide in order to obtain drugs intended for the treatment of Smith-Magenis syndrome.

Abstract translation: 本发明涉及到用于治疗Smith-Magenis综合征的药物的用途，所述agomelatine或N- [2-（7-甲氧基-1-萘基）乙基]乙酰胺用于获得药物。

公开(公告)号：AU2007201527B2

公开(公告)日：2012-08-09

申请号：AU2007201527

申请日：2007-04-05

Applicant: SERVIER LAB

Inventor： DELALLEAU BRUNO ,  FABIANO AGNES ,  MILLAN MARK ,  MOCAER ELISABETH

IPC: A61K31/165 ,  A61P25/22

Abstract: USE OF AGOMELATINE IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF GENERALIZED ANXIETY DISORDER 5 The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1 naphthyl)ethylacetamide, in obtaining medicaments intended for the treatment of Generalized Anxiety Disorder.

公开(公告)号：AU2007234614B2

公开(公告)日：2012-06-14

申请号：AU2007234614

申请日：2007-11-22

Applicant: SERVIER LAB

Inventor： FABIANO AGNES ,  MOCAER ELISABETH

IPC: A61K31/165 ,  A61P5/00 ,  A61P25/00 ,  A61P25/20

Abstract: The present invention relates to the use of agomelatine, N-[2-(7-methoxy-1 naphthyl)ethyl]acetamide, for the treatment of Smith-Magenis syndrome.

公开(公告)号：MY145139A

公开(公告)日：2011-12-30

申请号：MYPI20071976

申请日：2007-11-13

Applicant: SERVIER LAB

Inventor： MOCAER ELISABETH ,  FABIANO AGNES

IPC: A61K31/165

Abstract: USE OF AGOMELATINE IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF SMITH-MAGENIS SYNDROME THE PRESENT INVENTION RELATES TO THE USE OF AGOMELATINE, OR N-[2-(7-METHOXY-L- NAPHTHYL)ETHYL]ACETAMIDE, IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF SMITH- MAGENIS SYNDROME.

公开(公告)号：RS51676B

公开(公告)日：2011-10-31

申请号：RSP20110157

申请日：2007-11-23

Applicant: SERVIER LAB

Inventor： MOCAER ELISABETH ,  FABIANO AGNES

IPC: A61K31/165 ,  A61P25/00

Abstract: Use of agomelatine (I) or its hydrates, crystalline forms and acid or base addition salts, to obtain a drug to treat Smith Magenis syndrome, is claimed. An independent claim is included for a composition comprising (I) optionally in combination with excipients. ACTIVITY : Antidepressant; Hypnotic; Cardiovascular-Gen.; Anorectic. MECHANISM OF ACTION : 5-Hydroxytryptamine-2C antagonist; Melatoninergic receptor agonist.

公开(公告)号：SI1929999T1

公开(公告)日：2011-06-30

申请号：SI200730595

申请日：2007-11-23

Applicant: SERVIER LAB

Inventor： MOCAER ELISABETH ,  FABIANO AGNES

IPC: A61P25/00 ,  A61K31/165

公开(公告)号：PL1842535T3

公开(公告)日：2011-01-31

申请号：PL07290420

申请日：2007-04-06

Applicant: SERVIER LAB

Inventor： DELALLEAU BRUNO ,  FABIANO AGNES ,  MILLAN MARK ,  MOCAER ELISABETH

IPC: A61K31/165 ,  A61P25/22

公开(公告)号：HRP20100577T1

公开(公告)日：2010-11-30

申请号：HRP20100577

申请日：2010-10-21

Applicant: SERVIER LAB

Inventor： DELALLEAU BRUNO ,  FABIANO AGNES ,  MILLAN MARK ,  MOCAER ELISABETH

IPC: A61K31/165 ,  A61P25/22

Abstract: Use of agomelatine or N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide or its hydrates, crystalline forms and acid/base additive salts, to obtain a drug for the treatment of generalized anxiety disorders. An independent claim is included for a composition comprising agomelatine, optionally in combination with excipients, for the manufacture of a drug to treat generalized anxiety disorders. ACTIVITY : Tranquilizer; Antidepressant; Hypnotic; Cardiovascular-Gen; Gastrointestinal-Gen; Anorectic. MECHANISM OF ACTION : Melatoninergic system receptors agonist; 5-HT2c receptor antagonist.

公开(公告)号：SI1842535T1

公开(公告)日：2010-10-29

申请号：SI200730345

申请日：2007-04-06

Applicant: SERVIER LAB

Inventor： DELALLEAU BRUNO ,  FABIANO AGNES ,  MILLAN MARK ,  MOCAER ELISABETH

IPC: A61K31/165 ,  A61P25/00

公开(公告)号：GEP20094743B

公开(公告)日：2009-07-27

申请号：GEAP2007009966

申请日：2007-04-05

Applicant: SERVIER LAB

Inventor： MOCAER ELISABETH ,  MILLAN MARK ,  FABIANO AGNES ,  DELALLEAU BRUNO

IPC: A61P25/22 ,  A61K31/165

Abstract: Use of agomelatine or N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide or its hydrates, crystalline forms and acid/base additive salts, to obtain a drug for the treatment of generalized anxiety disorders. An independent claim is included for a composition comprising agomelatine, optionally in combination with excipients, for the manufacture of a drug to treat generalized anxiety disorders. - ACTIVITY: Tranquilizer; Antidepressant; Hypnotic; Cardio¬vas¬cu¬lar-Gen; Gastrointestinal-Gen; Anorectic. – ME¬CHANISM OF ACTION : Melatoninergic system receptors agonist; 5-HT2c receptor antagonist.